A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 16 Sep 2016 Results assessing postprandial glucose (PPG) metabolism, lipid (PPL) metabolism and gastric emptying (GE), presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2016 Results confirming semaglutide-induced body weight loss through various possible mechanisms, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.